UroGen
is a New Jersey-based biotechnology company that researches and develops novel therapies for the treatment of cancer and urological diseases... Read moreUroGen
is a New Jersey-based biotechnology company that researches and develops novel therapies for the treatment of cancer and urological diseases... Read more
News
Jun 02, 2026
Benzinga
UroGen: UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO (mitomycin) for pyelocalyceal solution
Jun 02, 2026
Benzinga
UroGen: UroGen Pharma Announces Settlement And Licens...
Jun 01, 2026
Yahoo
UroGen: UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 15, 2026
FinanzNachrichten
UroGen: UroGen Pharma Ltd.: UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
May 13, 2026
GlobalNewswire
Press Release: UroGen : ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
May 13, 2026
RTTNews
UroGen: Urogen Shows 3-Year Durability In ENVISION Trial Of ZUSDURI For Recurrent Bladder Cancer
May 09, 2026
Yahoo
UroGen: Assessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch Momentum
May 07, 2026
Yahoo
UroGen: Urogen Pharma Q1 Earnings Call Highlights
May 07, 2026
Seeking Alpha
UroGen: UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
May 07, 2026
Yahoo
UroGen: UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Competitors
1
2
3
4
5
6
7
8
9
10